Everett Vokes, MD, is the John E. Ultmann Distinguished Service Professor and Chair of the Department of Medicine at the University of Chicago, and physician-in-chief at the University of Chicago Medicine
Dr. Vokes earned his medical degree at the University of Bonn Medical School in Bonn, Germany. He completed his clerkship at St Luke’s Hospital in Sydney, Australia, and an internship at Malteser Hospital in Bonn. He completed his internship and residency in internal medicine at the Ravenswood Hospital Medical Center in Chicago, a senior residency in internal medicine at the University of Southern California-Los Angeles County Hospital, and a fellowship in hematology-oncology at the University of Chicago.
A clinical and translational investigator, Dr. Vokes focuses on the biology and treatment of lung and head and neck cancers and the interaction of chemotherapy and radiation and integration of targeted and immune-based agents. He established the intellectual and clinical basis of national trials investigating concomitant chemoradiotherapy and other approaches to providing multispecialty care and leads clinical and translational investigations both at the university and nationally.
Dr. Vokes is a member of professional organizations including the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer, among others. He is an elected member of the American Society of Clinical Investigation and American Association of Professors and serves on the editorial boards of several oncology journals and is a reviewer for various publications.
To his credit are more than 80 book chapters and 500 papers published in such journals as New England Journal of Medicine, Journal of Clinical Oncology, Annals of Oncology, and Journal of Thoracic Oncology, to name a few. Dr. Vokes has presented his work at numerous medical congresses.
Early dynamics of circulating tumor HPV-DNA with neoadjuvant chemotherapy and response-adapted de-escalation in human papillomavirus-associated oropharyngeal cancer.
Early dynamics of circulating tumor HPV-DNA with neoadjuvant chemotherapy and response-adapted de-escalation in human papillomavirus-associated oropharyngeal cancer. Clin Cancer Res. 2025 May 27.
PMID: 40423530
Radiation-induced amphiregulin drives tumour metastasis.
Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025 May 14.
PMID: 40369065
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial.
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
PMID: 40048190
Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer.
Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer. J Clin Oncol. 2025 Mar 27; JCO2402355.
PMID: 40146965
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas. Oral Oncol. 2025 Apr; 163:107207.
PMID: 40043423
PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands.
PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. J Exp Clin Cancer Res. 2025 Jan 11; 44(1):11.
PMID: 39794830
Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive CYP2D6 Genotyping in Cancer Palliative Care.
Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive CYP2D6 Genotyping in Cancer Palliative Care. J Pain Res. 2024; 17:4187-4196.
PMID: 39717756
Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance.
Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance. Cancer. 2025 Jan 01; 131(1):e35663.
PMID: 39580636
Epigenomic exploration of disease status of EGFR-mutated non-small cell lung cancer using plasma cell-free DNA hydroxymethylomes.
Epigenomic exploration of disease status of EGFR-mutated non-small cell lung cancer using plasma cell-free DNA hydroxymethylomes. Cancer Commun (Lond). 2025 Jan; 45(1):51-55.
PMID: 39527101
Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538.
Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538. JAMA Netw Open. 2024 Oct 01; 7(10):e2440673.
PMID: 39446327